CervoMeddDirector Boger's $3M insider buy and updated presentation
Director Boger's $3M insider buy and updated presentation drive CRVO's 45% premarket surge
- CervoMed filed 8-K June 15 posting new investor presentation on clinical data, Phase 3 partnering for neflamapimod in DLB, and financial runway to Q2 2027.
- Director Joshua S. Boger and related trust disclosed buying 955K units at $3.14 (~$3M) in June 11 private placement, viewed as strong vote of confidence.
- June 10 announcement raised $10.5M gross; proceeds fund R&D and strategic partnership pursuit for dementia with Lewy bodies program.
- Stock closed June 15 near $2.48 before jumping ~44-55% in June 16 premarket trading to around $3.55 amid elevated volume.
- Presentation covers positive prior neflamapimod DLB trial results, upcoming nfvPPA biomarker data, and ALS Phase 2a initiation.
- Timing of Form 4 filings and 8-K aligns precisely with surge; amplified by retail chatter in neuro/rare disease biotech theme.
- No new clinical trial results released; move reflects digestion of insider signal and updated corporate materials.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.